𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Syndrome of opsoclonus–myoclonus in hyperosmolar nonketotic coma

✍ Scribed by Kiichiro Matsumura; Masahiro Sonoh; Akira Tamaoka; Manabu Sakuta


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
233 KB
Volume
18
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Autoantigen diversity in the opsoclonus-
✍ Luis Bataller; Myrna R. Rosenfeld; Francesc Graus; Juan J. Vilchez; Nai-Kong V. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract Despite circumstantial evidence that opsoclonus‐myoclonus (OM) is often immune mediated, no specific autoantigen has been identified. Using sera of 21 patients with several types of OM (idiopathic, associated to small cell lung cancer, and associated to neuroblastoma), we probed a brain

Electrophysiological observations in idi
✍ Katrina A. Gwinn; Dr. John N. Caviness 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 467 KB

## Abstract To supplement existing knowledge regarding the pathophysiology of the opsoclonus‐myoclonus syndrome, electrophysiological findings are reported in three patients with idiopathic opsoclonus–myoclonus. Surface electromyography (EMG) revealed <100‐ms synchronous discharges correlating with

A case of poststreptococcal opsoclonus-m
✍ Pooja Dassan; Charles Clarke; David J. Sharp 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

## Abstract High antistreptococcal antibody titer (ASOT) was measured in a 31‐year‐old Caucasian lady presenting with opsoclonus and myoclonus. She was treated with oral steroids and 8 weeks after the onset of symptoms she had a normal ASOT and only mild residual symptoms. This is one of the first

Electrophysiological evidence of cerebra
✍ Hiroshi Sakuma; Yuko Shimizu; Yoshiaki Saito; Kenji Sugai; Masumi Inagaki; Makik 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn